Friday, AstraZeneca PLC (AZN) along with Daiichi Sankyo (DSKYF.PK) announced that Datroway has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer.
The approval comes after Priority Review by the U.S. Food and Drug Administration based on results from the TROPION-Breast02 phase 3 trial, which demonstrated a statistically significant and clinically meaningful 5.0-month improvement in median overall survival.
Based on the findings of the trial, Datroway has been included in the NCCN Clinical Practice Guidelines in Oncology as a Category 1 Preferred first-line treatment option.
Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo, Inc., commented, "With this approval, Datroway is now approved for three indications in the U.S., including two for breast cancer, underscoring its potential to play an important role across tumor types."
Currently, AZN is trading at $187.65, down 1.10 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.